RxDoctor Payments Data

Ajay Pandey, MD

Neurology · South Miami, FLNPI 1124276308

Payments from drug & device makers

$15,085in general payments, 2019–2025

Across 794 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novartis$1K
  • UCB, Inc.$946
  • Neurocrine Biosciences, Inc.$736
  • Teva Pharmaceuticals USA, Inc.$665
  • Lilly USA, LLC$658
  • plus $8K from 50 others

What the payments were for

  • Speaking & faculty fees$1301%
  • Food & beverage$14,80898%
  • Education$1471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)173$2,972
Novartis66$1,294
UCB, Inc.28$946
Neurocrine Biosciences, Inc.61$736
Teva Pharmaceuticals USA, Inc.34$665
Lilly USA, LLC30$658
Pfizer41$547
Argenx US, Inc.22$486
Acadia Pharmaceuticals Inc26$468
Amneal Pharmaceuticals LLC20$466
Amgen(2 entities)22$449
Biogen19$420
Lundbeck LLC17$400
Eisai Inc.19$347
SK Life Science, Inc.15$345
EMD Serono, Inc.14$253
Otsuka America Pharmaceutical, Inc.12$252
Adamas Pharmaceuticals, Inc.17$225
Biohaven Pharmaceuticals, Inc.9$192
Johnson & Johnson(2 entities)6$190
Acorda Therapeutics, Inc9$179
Takeda Pharmaceuticals U.S.A., Inc.7$175
Tanabe Pharma America, Inc.7$173
E.r. Squibb & Sons, L.L.C.8$165
Aprecia Pharmaceuticals, LLC10$140
Neurelis, Inc.7$128
Mallinckrodt Hospital Products Inc.5$123
Supernus Pharmaceuticals, Inc.8$115
Azurity Pharmaceuticals, Inc.5$112
Boston Scientific3$109
AstraZeneca(2 entities)7$108
Kyowa Kirin, Inc.7$108
Avion Pharmaceuticals7$102
CSL Behring4$93
Bristol Myers Squibb4$83
MDD US Operations, LLC4$76
Genentech USA, Inc.4$74
Upsher-smith Laboratories LLC4$74
Livanova USA, Inc.4$71
Biohaven Pharmaceutical Holding Company Ltd.3$65
Avanir Pharmaceuticals, Inc.3$56
Axsome Therapeutics, Inc.2$53
TG Therapeutics, Inc.2$48
Corium, LLC3$46
Abbott2$46
Alfasigma USA, Inc.2$38
Merz Pharmaceuticals, LLC2$37
Banner Life Sciences, LLC2$36
Sobi, Inc1$22
Scilex Pharmaceuticals Inc.1$18
Cala Health, Inc.1$17
Sunovion Pharmaceuticals Inc.1$17
Hyperfine Operations, Inc.1$17
Akcea Therapeutics, Inc.1$17
Cycle Pharmaceuticals Inc1$16
Nevro Corp.1$15

How this compares

$15,085 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$97,310
Medicare patients
187
Services billed
570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5016$60,398
Nurtec OdtRimegepant Sulfate15$25,542
RytaryCarbidopa/Levodopa29$16,076
LamictalLamotrigine11$11,077
Memantine Hcl67$1,452
Donepezil Hcl179$1,227
Levetiracetam59$1,213
Ropinirole Hcl23$981
Gabapentin54$805
Memantine Hcl ErMemantine Hcl11$711
Pregabalin19$569
Lamotrigine24$567
Carbidopa-LevodopaCarbidopa/Levodopa47$442
Cyclobenzaprine Hcl12$313
Lacosamide15$308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$175$60,39816 claims
PfizerNurtec Odt$547$25,54215 claims
Amneal Pharmaceuticals LLCRytary$466$16,07629 claims
Upsher-smith Laboratories LLCTopiramate$74$7723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,434 neurology providers in Florida.

Other neurology in South Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →